RENX vs. KOO, COG, INHC, FDBK, IQAI, DVRG, TRLS, SENS, EMIS, and CRW
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Kooth (KOO), Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), DeepVerge (DVRG), Trellus Health (TRLS), Sensyne Health (SENS), EMIS Group (EMIS), and Craneware (CRW). These companies are all part of the "health information services" industry.
Renalytix vs. Its Competitors
Renalytix (LON:RENX) and Kooth (LON:KOO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
25.6% of Renalytix shares are owned by institutional investors. Comparatively, 26.4% of Kooth shares are owned by institutional investors. 5.5% of Renalytix shares are owned by company insiders. Comparatively, 30.7% of Kooth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Renalytix and Renalytix both had 1 articles in the media. Renalytix's average media sentiment score of 0.36 beat Kooth's score of 0.00 indicating that Renalytix is being referred to more favorably in the media.
Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.
Kooth has a consensus target price of GBX 365, indicating a potential upside of 151.72%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Renalytix.
Renalytix has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Kooth has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Kooth has a net margin of 7.89% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Kooth's return on equity.
Summary
Kooth beats Renalytix on 11 of the 15 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
This page (LON:RENX) was last updated on 10/6/2025 by MarketBeat.com Staff
